Pharma Partnerships Brainify.AI is backed by Merck GHI Fund, Northpond, and Kodori VC, and is a member of J&J Labs and Merck DSS, signaling strong strategic interest from major pharma. This creates opportunities for co development, platform licensing, and integration in depression drug development. Target enterprise licenses, funded pilots, data collaborations, and joint go to market with large pharma teams.

Growth Readiness With revenue in the 0 to 1 million range and about 11 to 50 employees, Brainify.AI operates as an early stage company likely seeking scale through partnerships. Offer flexible engagement models such as funded pilots, milestone based deals, and pre validated data packages to de risk collaborations.

Validation Prestige The company has earned recognition at Nebius AI Discovery Awards and has presented at the World Economic Forum and Biotech Showcase. This credibility can accelerate introductions to decision makers, enabling faster pilots, case studies, and press opportunities that support enterprise selling.

Clinical Collaboration Clerkenwell Health partnership and emphasis on assessment, diagnosis, and treatment of depression indicate a need for clinical data access, patient cohorts, and trial readiness. Sales opportunities include data pipeline integrations, EHR interoperability, patient stratification tools, and regulatory grade analytics to support trial design and regulatory submissions.

Industry Engagement Active conference participation and award recognition position Brainify.AI to leverage events for lead generation. Propose tailored outreach to pharma business development teams during upcoming events, sponsorships or speaking slots to accelerate introductions and partnerships.